Millendo Therapeutics
Founded Year
2012Stage
Reverse Merger | IPOTotal Raised
$128.29MAbout Millendo Therapeutics
Millendo Therapeutics, previously known as Atterocor, is a drug development company focused on a treatment for adrenal cancer. The company seeks to develop adrenal-targeting therapy for the treatment of adrenocortical carcinoma (ACC) patients.
Millendo Therapeutics Headquarter Location
301 North Main Street Suite 100
Ann Arbor, Michigan, 48104,
United States
734-845-9000
Expert Collections containing Millendo Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Millendo Therapeutics is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Millendo Therapeutics Patents
Millendo Therapeutics has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/25/2015 | 1/17/2017 | Piperazines, Piperidines, National supreme courts, Synthetic opioids, Adrenal gland disorders | Grant |
Application Date | 9/25/2015 |
|---|---|
Grant Date | 1/17/2017 |
Title | |
Related Topics | Piperazines, Piperidines, National supreme courts, Synthetic opioids, Adrenal gland disorders |
Status | Grant |
Latest Millendo Therapeutics News
Jul 15, 2021
07/15/2021 | 09:32am EDT Message : *Required fields NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. (Note: You may have to copy this link into your browser then press the [ENTER] key.) InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. View original content to download multimedia: https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-verb-technology-casper-sleep-millendo-therapeutics-lipocine-or-hepion-pharmaceuticals-301334728.html SOURCE InvestorsObserver
Millendo Therapeutics Web Traffic
Millendo Therapeutics Rank
When was Millendo Therapeutics founded?
Millendo Therapeutics was founded in 2012.
Where is Millendo Therapeutics's headquarters?
Millendo Therapeutics's headquarters is located at 301 North Main Street, Ann Arbor.
What is Millendo Therapeutics's latest funding round?
Millendo Therapeutics's latest funding round is Reverse Merger.
How much did Millendo Therapeutics raise?
Millendo Therapeutics raised a total of $128.29M.
Who are the investors of Millendo Therapeutics?
Investors of Millendo Therapeutics include OvaScience, Frazier Healthcare Partners, New Enterprise Associates, Roche Venture Fund, 5AM Ventures and 7 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.